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Abstract
Although nerve agent use is prohibited, concerns remain for human exposure to nerve agents 
during decommissioning, research, and warfare. Exposure can be detected through the analysis of 
the hydrolysis products in urine as well as blood. An analytical method to detect exposure to five 
nerve agents, including VX, VR (Russian VX), GB (sarin), GD (soman) and GF (cyclosarin), 
through the analysis of the hydrolysis products, which are the primary metabolites, in serum has 
been developed and characterized. This method uses solid phase extraction coupled with high 
performance liquid chromatography for separation and isotopic dilution tandem mass 
spectrometry for detection. An uncommon buffer of ammonium fluoride was used to enhance 
ionization and improve sensitivity when coupled with hydrophilic interaction liquid 
chromatography resulting in detection limits from 0.3–0.5 ng/mL. The assessment of two quality 
control samples demonstrated high accuracy (101–105%) and high precision (5–8%) for the 
detection of these five nerve agent hydrolysis products in serum.
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Organophosphorus nerve agents are highly toxic compounds that were originally developed 
as potent pesticides in the 1930s. Since that initial discovery more nerve agents have been 
synthesized and stockpiled for warfare purposes. Although use of these compounds has been 
limited in recent years [1], concerns remain that nerve agents will be used for non-
sanctioned warfare or terrorist activities. Stockpiles throughout the world are gradually 
being decommissioned [1] and laboratory research to improve treatments for exposed 
persons is being pursued [2, 3]. These activities may result in accidental human contact with 
nerve agents; therefore, the improved and expanded ability to assess human exposure to 
nerve agents is needed.
Following entry into the human body, nerve agents are either hydrolyzed or bound to 
acetylcholinesterase, butyrylcholinesterase, and other non-specific proteins. The binding to 
the acetylcholinesterase is the action that results in symptoms including miosis, seizures, and 
potentially death [1]. The hydrolysis products, also known as nerve agent metabolites, are 
readily excreted in the urine, but have also been detected in blood [4–6]. More specifically, 
human exposure to VX was identified in serum using gas chromatography/mass 
spectrometry (GC/MS) to measure the hydrolysis product, ethyl methylphosphonic acid. In 
this exposure case which resulted in death, the amount of metabolite from VX was 
determined to be 125 μg/mL [5]. Additionally, the hydrolysis products were detected in 
minipig blood using liquid chromatography-tandem mass spectrometry (LC/MS/MS) [4] 
following exposures to sarin and cyclosarin.
These hydrolysis compounds have been extensively quantitated in urine through various 
analytical methods. Gas chromatography coupled with mass spectrometry or tandem mass 
spectrometry has been used with success, although a derivatization step is required [7–9]. To 
avoid the additional derivatization, liquid chromatography coupled with mass spectrometry 
or tandem mass spectrometry has been applied, achieving sensitivities on the order of pg/mL 
in urine [10–13].
In most cases, sample preparation, including liquid-liquid extraction (LLE) and solid phase 
extraction (SPE), was necessary to achieve these low levels of detection. Solid phase 
extraction was cited more often than LLE, most likely due to the ease of use and potential 
for automation. The different solid phase extraction methods used for these compounds, 
included aqueous normal phase [10, 11], reversed phase [4], anion exchange [12, 14], and 
zirconia [14, 15]. However, for the extraction of nerve agent metabolites from serum, only 
LLE and reversed phase SPE were used [4–6].
An analysis method which includes the other nerve agent metabolites resulting from soman 
and VR exposure is needed, since only three nerve agent metabolites, EMPA, IMPA and 
CMPA, were previously quantitated in serum [4–6]. Although the amount of metabolite 
present in biological matrices has not been related to dose in humans, a quantitative value is 
still desired to obtain as much information regarding the relative amount of exposure as 
possible to differentiate between exposed and unexposed persons. Given this focus, an assay 
with high sensitivity is desired above a quantitative method designed to capture all exposure 
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levels. Additionally, this method should detect exposure to all five nerve agents within a 
single, high-throughput, and automated analysis. This study documents the development of a 
SPE-LC/MS/MS analysis for five nerve agent hydrolysis products in human serum which 
are indicative of exposure to sarin (GB), soman (GD), cyclosarin (GF), VX and VR.
Methods and Materials
Materials
The analytes evaluated for this method were the following: EMPA (ethyl methylphosphonic 
acid, CAS 1832-53-7), the metabolite of VX (O-ethyl S-(2-diisopropylaminoethyl) 
methylphosphonothioate, CAS 50782-69-9); IMPA (isopropyl methylphosphonic acid, CAS 
1832-54-8), the metabolite of GB (isopropyl methylphosphonofluoridate CAS 107-44-8); 
PMPA (pinacolyl methylphosphonic acid, CAS 616-52-4), the metabolite of GD (pinacolyl 
methylphosphonofluoridate, CAS 96-64-0); CMPA (cyclohexyl methylphosphonic acid, 
CAS 1932-60-1), the metabolite of GF (cyclohexyl methylphosphonofluoridate, CAS 
329-99-7); MMPA (2-(methyl)propyl methylphosphonic acid, CAS 1604-38-2), the 
metabolite of VR (O-2-(methyl)propyl S-2-(diethylaminoethyl) methylphosphonothioate. 
CAS 159939-87-4).
The internal standards were isotopically labeled as follows: EMPA, ethyl-D5; IMPA, 
isopropyl-13C3; PMPA, trimethylpropyl-13C6; CMPA, cyclohexyl-13C6; IMPA, 
methylphosphonyl-13C. The structures of the organophosphorus metabolites and internal 
standards are shown in Figure 1.
The analytical calibrators were prepared at concentrations of 0.5, 1.0, 2.0, 5.0, 10, 25, 50, 
100 ng/mL of each analyte in serum; the quality control samples were prepared at 4.0 and 40 
ng/mL of each analyte in serum. A primary stock (20 μg/mL of each analyte in methanol) 
purchased from Cerilliant Corporation (Round Rock, TX) was used to make stock solution I 
(4.0 μg/mL) and stock solution II (0.2 μg/mL). Stock solution I was prepared by aliquoting 
400 μL 20 μg/mL stock to a glass vial containing 1600 μL of serum. The second stock 
solution was prepared by pipetting 100 μL of stock solution I to a glass vial containing 1900 
μL of serum. Calibrators 0.5, 1.0, 2.0, and 5.0 ng/mL were made by aliquoting 25, 50, 100, 
250 μL, respectively, of stock solution II to 10.0 mL volumetric flasks. Calibrators 10, 25, 
50, and 100 ng/mL were prepared by delivering 25, 63, 125, and 250 μL, respectively, of 
stock solution I to their appropriate 10.0 mL volumetric flask. Quality control low (4.0 
ng/mL) and quality control high (40 ng/mL) were prepared by adding 200 μL of stock 
solution II and 100 μL of stock solution I, respectively, to 10.0 mL volumetric flasks. An 
additional solution was prepared at 0.25 ng/mL in serum to evaluate the limits of detection 
for the assay, by delivering 17 μL of stock solution II to a 10.0 mL volumetric flask. Spiked 
samples, 0.75 and 3.0 ng/mL, were prepared by aliquoting 37.5, and 150 μL of stock 
solution II to their respective 10.0 mL volumetric flask. Spiked samples, 15, 70, and 90 
ng/mL were prepared by delivering 37.5, 175, and 225 μL of stock solution I into their 
respective 10.0 mL volumetric flasks. All volumetric flasks were filled to 10.0 mL using 
serum purchased from Tennessee Blood Services Corporation (Memphis, TN). The serum 
was pooled from five donors, shipped at 4°C, received two days later, and subsequently 
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stored at −20°C until use. Once prepared, all fortified samples, calibrators, and quality 
control samples were maintained at −20°C.
Internal standard was prepared by dilution of a 500 ng/mL aqueous mixture (Cerilliant 
Corporation, Round Rock, TX) to a concentration of 23.8 ng/mL in DI water.
Organic-free 18.2 MΩ Type I water from a purifier purchased from Aqua Solutions, Inc. 
(Jasper, GA) was used in these studies. Pelletized 98% ammonium fluoride was purchased 
from Alfa Aesar (Ward Hill, MA) and molecular biology grade DEPC-treated 5M 
ammonium acetate from CalBiochem (La Jolla, CA). HPLC-grade acetonitrile and methanol 
were purchased from Tedia (Fairfield, Ohio). All human serum was purchased from 
Tennessee Blood Services Corporation (Memphis, TN).
Sample preparation
To prepare samples for extraction, 25 μL of 23.8 ng/mL internal standard was aliquoted into 
each well of a 2 ml 96-well NUNC plate. Fifty microliters of well-mixed serum was added 
to the internal standard, followed by 1000 μl of acetonitrile. The plate was sealed using a 
sheet of Thermo Scientific Adhesive PCR Sealing Foil (Hudson, NH) and vortexed for 5 
minutes on a ThermoLab Systems Wellmix (Hudson, NH). The NUNC plate was then 
centrifuged for 5 minutes at 3000 rpm.
The solid phase extraction was automated by using the Life Science Zephyr (Hopkinton, 
MA). The Phenomenex Strata Si-1 SPE 96-well plate (55 μM, 70 Å, 100 mg) was pretreated 
with 1000 μl of 25% water in acetonitrile, followed by 1000 μl of acetonitrile. The entire 
sample mixture with precipitate was then loaded to the SPE 96-well plate, and rinsed by a 
two-step process of 1000 μl of acetonitrile, followed by 1000 μl of 7% water in acetonitrile. 
The solutions were pulled through the SPE 96-well plate using vacuum. The analytes were 
then eluted with 1000 μl of 28% water in acetonitrile and collected in a clean 96-well NUNC 
plate.
The eluent was heated at 70 °C under 25 psi of nitrogen in a TurboVap for 30 minutes and 
then evaporated to dryness after increasing flow rate to 70 psi. The lower initial flow rate 
eliminated solvent splashing. The sample was then reconstituted in 100 μl of 5% water in 
acetonitrile, mixed by pipetting twice, and transferred to a 150 μl 96-well PCR plate and 
sealed.
Instrumental analysis
The HPLC separation was performed using an Agilent 1200 HPLC with a well-plate 
autosampler (Santa Clara, CA). A Waters Atlantis® HILIC 2.1-mm × 50-mm with 3-μm 
particles (70% porosity)HPLC column was used (Milford, MA). This hydrophilic interaction 
chromatography (HILIC) column consists of high purity, non-bonded silica particles. The 
injector was programmed to draw 20 μL of sample and wash the injector needle for 10 s in 
the wash port using 50% water in acetonitrile. The sample was then injected onto the 
column using an isocratic mobile phase consisting of 92% acetonitrile and 8% 1.0 mM 
ammonium fluoride with an initial flow rate of 500 μL/min. Following elution of the 
analytes, the flow rate was increased to 1000 μL/min at 3.01 min to remove any late eluting 
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impurities. The flow rate returned to 500 μL/min at 5.01 min to ensure stable pressure for 
the following injection. This method allows a 5-min injection-to-injection cycle time.
The mass spectrometric analysis was performed using an API 4000 triple quadrupole QTrap 
mass spectrometer from Applied Biosystems (Foster City, CA) controlled by Analyst 
software. The mass spectrometer was operated in multiple-reaction-monitoring (MRM) 
mode using negative electrospray ionization with assisted heating. The specific operating 
conditions are listed in Table 1 with the proposed fragment ions.
The specific settings used were curtain gas (CUR), 10 psi; nebulizer gas (GS1), 40 psi; turbo 
gas (GS2), 40 psi; GS2 temperature (TEM), 550 °C; collision gas, nitrogen; collision gas 
(CAD), Medium, producing a gas pressure reading of 3.3 × 10−5 Torr; ionspray potential 
(IS), −4500 V; entrance potential (EP), −10; interface heater (IHE), on.
The data were analyzed using Analyst 1.5.2, which was provided with the instrument. This 
software is used to review the chromatograms for retention times, baselines and possible 
interferences. Quantitative analysis of the data by automated and manual integrations, linear 
regression, and calculation of accuracies and correlation coefficients was also performed 
with this software package. The chromatographic data were smoothed three times prior to 
integration with a bunching factor between 1 and 3, and fitted by linear regression using 1/x 
weighting.
Safety precautions
The techniques and materials in this method do not pose any special hazards. General 
considerations include exercising universal precautions, such as wearing appropriate 
personal protective equipment, when handling chemicals and serum samples. The high 
voltage employed in electrospray ionization should also be considered a hazard, and the 
safety interlocks provided by the instrument manufacturer should not be altered. For 
instrument-specific safety concerns, please consult the manufacturer.
Results and Discussion
Sample Preparation
Initial evaluation of a protein precipitation using acetonitrile or acetone for the sample 
preparation of these compounds from serum resulted in lower sensitivities than desired. As 
exposures may be small and/or a sample may be collected many hours to days following 
exposure, it is important to have the highest sensitivity possible. Additionally, the presence 
of interfering matrix components was detected in select transitions, which would negatively 
impact the specificity of the analysis. To accomplish the goals of sensitivity and specificity, 
additional sample preparation was necessary.
Solid phase extraction was selected for sample preparation due to automation and high 
throughput potentials. The initial solvents and volumes used for the extraction were selected 
from Swaim, et al [10] from urine sample extraction. The sorbent was conditioned with 
1000 μL of 25% water in acetonitrile, followed by 1000 μL of acetonitrile. After the sample 
mixture, comprised of 100 μL of serum, 25 μL of internal standard solution and 1000 μL of 
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acetonitrile) was loaded, the sorbent was rinsed with 1000 μL of acetonitrile, followed by 
1000 μL of 10% water in acetonitrile. Finally, the compounds were eluted using 1000 μL of 
25% water in acetonitrile and collected in a 2 mL 96-well NUNC plate. Using a serum 
matrix fortified at 10 ng/mL, each step within the solid phase extraction protocol was then 
evaluated in triplicate for optimal recovery. To evaluate the loading step, 50 μL of serum 
was diluted with acetonitrile, with additional deionized water as needed, to yield an aqueous 
solution of 7, 12 and 17%. The seven percent aqueous loading solution resulted in the 
highest responses with no detected breakthrough. Next, the second wash step was assessed 
at acetonitrile content ranging from 93 – 83%. The wash step of 93% acetonitrile yielded the 
highest recoveries with minimal losses detected. No adjustments were made to the elution 
composition as complete elution was achieved in one step with the 25% water/75% 
acetonitrile mixture. Final extraction recoveries, determined at 10.0 ng/mL and calculated by 
the ratio of the measured concentration to the spiked concentration, were as follows: EMPA, 
88% (standard deviation of 17), IMPA, 76%(13) MMPA , 92% (9.6)), PMPA, 94% (10), 
and CMPA , 95% (7.7). With the optimized solid phase extraction parameters, no analyte 
was detected within the two captured wash steps. Following the elution, a second elution 
step was evaluated to remove the analytes still remaining on the SPE. This second elution 
showed minimal (<1%) amounts of PMPA, CMPA and MMPA, approximately 5% of 
EMPA and no detectable IMPA remained on the SPE following the initial elution.
Separation and Detection
Previous studies have reported successful separation of these compounds with HILIC 
chromatography using an isocratic ammonium acetate buffer coupled with acetonitrile (14% 
20 mM ammonium acetate: 86% acetonitrile) as the mobile phase [10, 11]. This mobile 
phase composition was used as a starting point for the separation of these compounds and is 
shown in Figure 2b. Since the mass spectrometric intensity of these compounds has been 
augmented with the addition of various solvents [16] post column, alternative buffers were 
investigated to determine if increases in response could be achieved. Ammonium fluoride 
has been reported to result in the ionization of additional compounds and may in fact 
enhance ionization when using negative electrospray [17, 18]. With this information the 
HILIC chromatographic separation was evaluated replacing the 20 mM ammonium acetate 
buffer with 1 mM ammonium fluoride buffer. This change resulted in an increased signal for 
all compounds (Table 2), with an average 7.7-fold improvement in peak area response, with 
astandard deviation of the peak area response between the compounds was found to be 0.77. 
Using the 1 mM ammonium fluoride increased retention; therefore, to minimize runtime, the 
isocratic mobile phase composition was adjusted to 8% 1 mM ammonium fluoride and 92% 
acetonitrile to achieve retention factors of 4.6–6.1 (Figure 2a). This change also resulted in 
further 2-fold signal increase from the 14% ammonium fluoride mobile phase, which is 
equivalent to at least a 10-fold signal increase (Table 2), indicating the impact of higher 
acetonitrile content on the ionization efficiency of these compounds.
Method Characterization
Twenty sets of calibrators with QC samples were extracted and analyzed by LC-MS/MS to 
determine the precision and bias of this method over time. Multiple analysts prepared no 
more than two standard sets with QC samples per day over a period of 36 days. Quality 
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control characterization data are presented in Table 3. The inter-day relative standard 
deviations for both quality control samples for all five compounds were below 8% and the 
accuracy was between 101–105% for all compounds. These results confirm this method 
provides acceptable precision and accuracy for these compounds according to the FDA 
Bioanalytical Method Development Guidelines [19].
Limits of Detection
The limits of detection (LOD) for the five compounds were estimated using low level spiked 
serum with concentrations from 0.25 – 1.0 ng/mL. Each low level spiked sample was 
analyzed 20 times within a two-week period, with no more than five replicates within one 
day. The absolute values of the standard deviations were then plotted versus concentration 
with the intercept of the least-squares fit of this line equal to S0 with 3S0 being the LOD 
[20]. The LODs for this method were determined and reported in Table 3. These estimates, 
ranging from 0.25–0.50 ng/mL, exceed other methods developed for serum which reported 
limits of detection from 3.9 – 30 ng/mL for EMPA[5, 6] and 16 ng/mL for PMPA and 
CMPA [7].
Sample Analysis
One hundred individual serum samples were extracted and analyzed to evaluate the presence 
of nerve agent metabolites in the serum of persons with no known exposure. A 
representative sample is shown in Figure 3. No peaks were observed above the lowest 
calibration point; therefore, results above the detection limit would indicate that an exposure 
to these compounds has occurred
To evaluate accuracy and precision across the calibration range, serum samples were 
prepared at the following concentrations: 0.75, 3, 15, 70, and 90 ng/mL. These samples were 
extracted and analyzed five times to generate the statistical data presented in Table 4. The 
relative standard deviations for all five levels were less than 10%, with the exception of the 
0.75 ng/mL spike of IMPA which resulted in a variance of 18%. Similarly, the four highest 
levels resulted in accuracy between 96% and 112%. However, for the lowest spiked sample 
at a concentration of 0.75 ng/mL the accuracies were between 78–93%. This drop in 
accuracy and increase in variability at the low concentration may be due to the closeness of 
the value to the limit of detection.
To widen application of this method to samples with a metabolite concentration greater than 
100 ng/mL, a 4.0 μg/mL fortified sample was prepared in serum. This sample was diluted to 
4.0 and 40.0 ng/mL using blank serum; the diluted samples were then extracted and 
analyzed in triplicate. The average quantitated values ranged from 3.91–4.27 ng/mL and 
39.5–41.8 ng/mL for the two levels. When the quantitated values were calculated with the 
dilution factor, the accuracies ranged from 97.8–106%.
The stability of these compounds in serum stored for 6 months at −20°C was evaluated at 
4.0 ng/mL and 40.0 ng/mL. The stored samples were analyzed in triplicate and quantitated 
relative to freshly prepared calibrators. The concentrations of the two levels were within the 
10.0% of the original spiked concentration for all five analytes. Given the variability of the 
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method, these results indicated that the metabolites were stable for at least 6 months stored 
frozen.
Limitations
Due to a high background response resulting from the ammonium fluoride buffer, the initial 
transition selected for CMPA (177>79 m/z) did not result in a discernible peak within the 
reportable range. An alternative transition of 177>63 m/z was evaluated; however, this new 
transition was only detectable to about 1 ng/mL due to limited signal. Similarly, the 
confirmatory ion for PMPA was not consistently identified below 2 ng/mL due to a high 
background response. Previous publications have indicated that this background may be 
attributed to the impurities within the ammonium fluoride used for the buffer and potentially 
the interaction of this buffer with the stationary phase [18]. It should be noted that these 
issues were only detected in the confirmatory ions and do not affect the reported limits of 
detection for these compounds
Conclusions
A method to detect exposure to five nerve agents, including VX, VR, soman (GD), sarin 
(GB), and cyclosarin (GF) in serum has been developed and evaluated. The novel use of 
ammonium fluoride as the mobile phase buffer increased the ionization of the compounds up 
to 10-fold over the use of ammonium acetate, which substantially increased the sensitivity of 
this assay. Both the resulting precision and accuracy, 8% and 100–105% respectively, were 
within FDA recommendations. Since no peaks were detected within 100 individual serum 
samples with no known exposure to nerve agents, a response above the limit of detection is 
indicative of exposure to nerve agents. Given the potential for blood to clot and lyse, often 
due to poor handling or storage, which would impact the quality of the serum, future studies 
are planned to apply this assay to quantitate nerve agent exposure in non-ideal blood 
matrices.
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Structures of nerve agent metabolites and corresponding internal standards, * = 13C
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Chromatograms of 100 ng/mL calibrator in serum containing five nerve agent metabolites in 
different mobile phase compositions: a) 8% ammonium fluoride (1 mM)/92% acetonitrile, 
and b) 14% ammonium acetate (20 mM)/86% acetonitrile
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Chromatograms of 0.5 ng/mL serum calibrator containing five nerve agent metabolites (a) 
and blank serum (b)
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Table 2
Percent of peak area response relative to the buffer composition of 14% ammonium acetate (20 mM) with 
86% acetonitrile
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